Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Breast 1

Conditions

Recurrence 1Meningeal Carcinomatosis 1Glioblastoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
GDC-0084 × 90 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03765983 2026-05-27

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
17 enrolled 14 charts
Breast

Breast Neoplasms

NCT04192981 2026-04-22

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
21 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡